Lumosa Therapeutics Co., Ltd.

Taipei Exchange 6535.TWO

Lumosa Therapeutics Co., Ltd. Free Cash Flow Per Share for the year ending December 31, 2023: USD -0.07

Lumosa Therapeutics Co., Ltd. Free Cash Flow Per Share is USD -0.07 for the year ending December 31, 2023, a -13.54% change year over year. Free cash flow per share is the free cash flow generated per share. Indicates investment potential based on cash flow generation.
  • Lumosa Therapeutics Co., Ltd. Free Cash Flow Per Share for the year ending December 31, 2022 was USD -0.06, a 43.96% change year over year.
  • Lumosa Therapeutics Co., Ltd. Free Cash Flow Per Share for the year ending December 31, 2021 was USD -0.11, a -184.12% change year over year.
  • Lumosa Therapeutics Co., Ltd. Free Cash Flow Per Share for the year ending December 31, 2020 was USD -0.04, a 64.55% change year over year.
  • Lumosa Therapeutics Co., Ltd. Free Cash Flow Per Share for the year ending December 31, 2019 was USD -0.11.
Key data
Date Free Cash Flow Per Share Return on Assets (ROA) Return on Equity (ROE) Return on Capital Employed (ROCE)
Market news
Taipei Exchange: 6535.TWO

Lumosa Therapeutics Co., Ltd.

CEO Li Fang Pan
IPO Date July 16, 2015
Location
Headquarters No. 3-2, Park Street
Employees 47
Sector Health Care
Industries
Pharmaceuticals Biotechnology Clinical Trials
Description

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan. The company offers LT - 1001, an analgesic injection that has completed Phase III clinical trials for severe pain relief after surgery. It is also developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase Ib clinical trial for uremic pruritus; and LT2003, which is in pre-clinical stage for the treatment of oncology. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is based in Taipei, Taiwan.

StockViz Staff

January 15, 2025

Any question? Send us an email